New PARP Inhibitor Approved for Ovarian Cancer
The FDA approved a molecularly targeted therapeutic for the maintenance treatment of patients with recurrent epithelial ovarian and other cancers.
Progress Against Cancer
The FDA approved a molecularly targeted therapeutic for the maintenance treatment of patients with recurrent epithelial ovarian and other cancers.
The FDA issued the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma.
The FDA expanded the use of the immunotherapeutic pembrolizumab to include the treatment of certain patients with Hodgkin lymphoma.
A molecularly targeted therapeutic was approved for use in combination with any aromatase inhibitor for the treatment of postmenopausal women with a certain form of breast cancer.
The FDA expanded the use of a targeted therapy for a form of non-Hodgkin lymphoma called marginal zone lymphoma.
An immune checkpoint inhibitor – a form of immunotherapy – has had its use expanded for use in the treatment of bladder cancer.
The FDA approved a molecularly targeted therapeutic for women with advanced ovarian cancer linked to a BRCA gene mutation.
The U.S. FDA decision to approve nivolumab for head and neck cancer means nivolumab is now an approved treatment for five types of cancer.
The FDA approved a molecularly targeted therapeutic for treating certain patients with soft tissue sarcoma.
The FDA expanded the use of an immunotherapy to include the treatment of certain patients with lung cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More